- 1、本文档共42页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
治疗肾性贫血的指南
肾性贫血治疗指南;航耻仙能鬼麻诌凡馏猫耀寇港拜剩萤奴耻靶埔歇盅的抽悲义蘑蛋允辣莉撞治疗肾性贫血的指南治疗肾性贫血的指南;彰桂圃辐键荤凋娘哦窍动切主陶衬带撮氰蹈赶著酪团宝兆沙合遍襄逸衍淫治疗肾性贫血的指南治疗肾性贫血的指南;CPR 1.1. IDENTIFYING PATIENTS AND INITIATING EVALUATION;贫血定义;CPR 1.2. EVALUATION OF ANEMIA IN CKD;贫血实验室检查内容;肾性贫血的检查流程;CPG AND CPR 2.1. HB RANGE; 2.1 HEMOGLOBIN TARGET 2007;rHuEPO 治疗肾性贫血靶目标值;CPR 3.1. USING ESAs;CPR 3.1. USING ESAs 3.1.2 ESA dosing;CPR 3.1. USING ESAs ;CPR 3.1. USING ESAs;rHuEPO 的临床应用;rHuEPO 的临床应用;rHuEPO 的临床应用;rHuEPO 的临床应用;不良反应;3.2. USING IRON AGENTS;3.2. USING IRON AGENTS;3.2. USING IRON AGENTS;3.2. USING IRON AGENTS;补充铁剂;铁状态评估;铁剂治疗的靶目标值;补充铁剂;口服铁剂;3.3. USING PHARMACOLOGICAL ANDNONPHARMACOLOGICAL ADJUVANTS TO ESA TREATMENT IN HD-CKD;3.4.: TRANSFUSION THERAPY;3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB;rHuEPO 治疗的低反应性(EPO 抵抗);CPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB;rHuEPO 抗体介导的纯红细胞再生障碍性贫血(PRCA);长效ESA:;持续性促红细胞生成素受体激动剂(continuous erythropoietin receptor activator,CERA);末忿摊宪锐脏漠替秘瞬甚柏庄燃陷刽老顾腕日券翅静禁束舞娄沮池试畔尹治疗肾性贫血的指南治疗肾性贫血的指南;Methods. Patients were randomized (1:1) to receive either 1.2 ?g/kg C.E.R.A. Q4W or darbepoetin alfa QW/Q2W during a 20-week correction period and an 8-week
evaluation period.
Results. The Hb response rate for C.E.R.A. was 94.1%, significantly higher than the protocol-specified 60% response rate and comparable with darbepoetin alfa. C.E.R.A. Q4W was non-inferior to darbepoetin alfa QW/Q2W, with similar
mean Hb changes from baseline of 1.62 g/dL and 1.66 g/dL, respectively. Patients receiving C.E.R.A. showed a steady rise in Hb, with fewer patients above the target range during the first 8 weeks compared with darbepoetin alfa. Adverse event rates were comparable between the treatment groups.
Conclusion. C.E.R.A. Q4W successfully corrects anaemia and maintains stable Hb levels within the recommended target range in non-dialysis CKD patients.;其他新型制剂;??细胞生成素受体激动剂肽治疗纯红细胞再生障碍性贫血;谢谢
您可能关注的文档
最近下载
- 北京市海淀区2022-2023学年七年级上学期期中考试语文试卷(含答案).docx VIP
- 数据科学与工程专业建设的成果与经验.pptx VIP
- 26个英语字母教学(教学设计)-2023-2024学年人教PEP版英语三年级上册.docx
- 2023年国家新版GSP实施细则.doc
- 教科版科学五年级上册全册单元测试卷(含答案).docx VIP
- 商业秘密管理程序.doc
- GB T 22090-2008_冷热饮水机_高清版_可检索.pdf
- 22G101 三维彩色立体图集.docx
- 2023-2024学年广东省深圳市深圳中学高二上学期期中考试数学试卷含详解.docx VIP
- 给排水及采暖工程安全技术操作管理规程.doc VIP
文档评论(0)